Targeted Protein Degradation
joint with Ubiquitin Biology
Scientific Organizers: Rajesh Chopra, Nathanael Gray, Anita Gandhi and Georg Winter
Date: January 23 - 26, 2022
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
For important information on the coronavirus, please click here
This Keystone Symposia conference will highlight the recent exciting advances in targeting proteins for degradation as an alternative to conventional inhibitory small molecules and antibodies. Protein degradation can be undertaken by bifunctional molecules that bind the target for ubiquitin-mediated degradation by complexing them with Cereblon (CRBN), von Hippel-Lindau or other E3 ligases. Alternatively, E3 ligase components such as CRBN, DCAF15 and UBR7 can also be used as a ‘template’ to bind IMiD or sulphonamide-like compounds (the so called ‘Molecular Glues’) to degrade multiple context specific proteins by the selected E3 ligases. The ‘template or hijacking approach’ results in the degradation of neo-substrates, some of which would be difficult to drug using conventional approaches The chemical properties necessary for drug discovery, the rules by which neo-substrates are selected by ligase receptors and defining the optimal components of the ubiquitin proteasome for protein degradation are still to be fully elucidated. This conference will bring together early pioneers in the field, emerging scientists and experts from industry and academics to describe how these challenges are being addressed. Furthermore, experts who have used IMiD agents and proteasome inhibition in the clinic in real world practical applications of protein degradation agents have been invited to speak at this conference. Another unique aspect of this conference is with it being paired with the Keystone Symposia conference on Ubiquitin Biology. Protein ubiquitination regulates nearly every critical cellular pathway and emerging evidence has demonstrated that defects within the ubiquitin proteasome system can directly lead to human disease. This has fueled a recent expansion of drug development efforts to harness the ubiquitin proteasome system to both aid in its functionality during disease progression and to specify individual targets for degradation. By pairing these meetings, participants will be able to network and foster new collaborations between these two related areas of science.
Scholarship Deadline: October 12 2021 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies
Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.
We gratefully acknowledge the generous grant for this conference provided by:National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR003159-01
Funding for this conference was made possible (in part) by (PA-18-648) from the National (NCATS). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.